Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Leases: 2016-2018

Historic Capital Leases for ImmunityBio (IBRX) over the last 2 years, with Dec 2018 value amounting to $5.9 million.

  • ImmunityBio's Capital Leases rose 241.47% to $5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.9 million, marking a year-over-year increase of 241.47%. This contributed to the annual value of $5.9 million for FY2018, which is 241.47% up from last year.
  • Latest data reveals that ImmunityBio reported Capital Leases of $5.9 million as of Q4 2018, which was down 2.67% from $6.1 million recorded in Q3 2018.
  • ImmunityBio's 5-year Capital Leases high stood at $6.3 million for Q2 2018, and its period low was $1.7 million during Q1 2018.
  • Moreover, its 3-year median value for Capital Leases was $2.0 million (2016), whereas its average is $3.2 million.
  • Its Capital Leases has fluctuated over the past 5 years, first fell by 24.10% in 2017, then soared by 241.47% in 2018.
  • ImmunityBio's Capital Leases (Quarterly) stood at $2.0 million in 2016, then declined by 14.02% to $1.7 million in 2017, then spiked by 241.47% to $5.9 million in 2018.
  • Its Capital Leases was $5.9 million in Q4 2018, compared to $6.1 million in Q3 2018 and $6.3 million in Q2 2018.